Society for Neuroscience - 39th Annual Meeting. Part 1 - Novel therapies for the treatment of CNS disorders and pain.
The 39th Annual Meeting of the Society for Neuroscience (SFN), held in Chicago, included topics covering new therapeutic developments in the field of neuroscience. This conference report highlights selected presentations on nicotinic ACh receptor alpha7 agonists, cannabinoid CB2 receptor agonists, transient receptor potential channel antagonists, spinal mechanotransmission modulation, a COX-1 inhibitor, a NaV/CaV blocker, an opioid modulator and a novel triple reuptake inhibitor with potential antidepressant, anxiolytic and analgesic activity. Investigational drugs discussed include JN-711 (Novartis AG), NESS-070C5 and NESS-080C5 (both being developed by CeNeRx BioPharma Inc), RQ-00203078 (RaQualia Pharma Inc), HC-030031 (Cubist Pharmaceuticals Inc/Hydra Biosciences Inc), A-967079 (Abbott Laboratories), TRL-382 (Toray Industries Inc), NP-A (Neuromed Pharmaceuticals Inc) and RDC-5768 (Alkermes Inc).
Al-Shamahi
Asma
A
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. asma.al-shamahi@thomsonreuters.com
Kirkham
Konrad
K
Hookes
Livia
L
D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D002491:Central Nervous System Agents / Q000494:pharmacology / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000503:physiopathology; D015507:Drugs, Investigational / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D010146:Pain / Q000188:drug therapy* / Q000503:physiopathology
D000700:Analgesics; D002491:Central Nervous System Agents; D015507:Drugs, Investigational